证券代码：002868 证券简称：绿康生化 公告编号：2024-050 绿康生化股份有限公司 关于召开 2023 年度股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 绿康生化股份有限公司（以下简称"公司"或"绿康生化"）于 2024 年 4 月 28 日召开第四届董事会第四十一次会议审议通过了《关于召开公司 2023 年度股 东大会的议案》，决定于 2024 年 5 月 20 日 15:00 召开公司 2023 年度股东大会。 具体内容详见公司于 2024 年 4 月 30 日在《证券日报》和巨潮资讯网 （http://www.cninfo.com.cn）披露的《关于召开 2023 年度股东大会的通知》（公 告编号：2024-046）。 现将具体事项再次提示如下： 一、会议召开的基本情况 1、股东大会届次：2023 年度股东大会 2、会议召集人：公司董事会 3、会议召开的合法、合规性：本次会议的召开符合有关法律、行政法规、 部门规章、规范性文件和《公司章程》的规定。 4、现场会议召开时间：2024 年 5 月 20 日（星期一）15:00 ...

证券代码：002868 证券简称：绿康生化 公告编号：2024-049 绿康生化股份有限公司 关于部分监事、高级管理人员减持计划 实施完成的公告 公司监事冯真武、楼丽君，高级管理人员李俊辉、黄辉、鲍忠寿保证 向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述 或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息 一致。 绿康生化股份有限公司（以下简称"公司"或"绿康生化"）于 2024 年 1 月 13 日在巨潮资讯网（http://www.cninfo.com.cn）披露了《关于公司部分监事、高 级管理人员减持股份预披露的公告》（公告编号：2024-006）。 1、股东冯真武拟自本减持计划公告之日起 15 个交易日后的 3 个月内通过 集中竞价交易方式（根据相关法律法规规定禁止减持的期间除外）减持本公司股 份不超过 28,931 股（占公司总股本比例的 0.019%）。 2、股东楼丽君拟自本减持计划公告之日起 15 个交易日后的 3 个月内通过 集中竞价交易方式（根据相关法律法规规定禁止减持的期间除外）减持本公司股 份不超过 13,821 股（占公司总股本比例的 0.00 ...

证券代码：002868 证券简称：绿康生化 公告编号：2024-048 会议召开时间：2024 年 05 月 15 日（星期三）15:00-16:00 会议召开方式：网络互动方式 会议召开地点：价值在线（www.ir-online.cn） 会议问题征集：投资者可于 2024 年 05 月 15 日 前访 问网址 https://eseb.cn/1elmvx4BkNq 或使用微信扫描下方小程序码进行会前提问， 公司将通过本次业绩说明会，在信息披露允许范围内就投资者普遍关注 的问题进行回答。 一、说明会召开的时间、地点和方式 会议召开时间：2024 年 05 月 15 日（星期三）15:00-16:00 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 二、参加人员 董事长、总经理：赖潭平 绿康生化股份有限公司 关于举办2023年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 绿康生化股份有限公司（以下简称"公司"）已于 2024 年 04 月 30 日在巨 潮资讯网上披露了《2023 年年 ...

证券代码：002868 证券简称：绿康生化 公告编号：2024-047 绿康生化股份有限公司 关于职工监事选举结果的公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 绿康生化股份有限公司（以下简称"公司"或"绿康生化"）第四届监事会三年 任期即将届满，为保证监事会换届工作的顺利进行，根据《公司法》《公司章程》 的有关规定，公司于2024年5月9日召开第五届职工代表大会第二次会议，经参会 职工代表认真审议，同意选举孟君先生作为公司第五届监事会职工代表监事（个 人简历详见附件）。 公司第五届监事会由3名监事组成，其中职工代表监事的比例为三分之一。孟 君先生将与公司2023年度股东大会选举产生的两名非职工代表监事共同组成公 司第五届监事会，任期自公司2023年度股东大会审议通过相关议案之日起三年。 《绿康生化股份有限公司职工代表大会决议》。 特此公告。 绿康生化股份有限公司 监 事 会 2024 年 5 月 11 日 1 附件：绿康生化股份有限公司第五届监事会职工代表监事简历 孟君先生：中国国籍，无境外永久居留权，1980 年出生，本科学历。历任公 司提炼车间设 ...

Financial Performance - The company reported a significant increase in revenue, with a year-on-year growth of 15% in 2023 [19]. - The company's operating revenue for 2023 was CNY 507,004,856.86, representing a 53.71% increase compared to CNY 329,850,238.49 in 2022 [25]. - The net profit attributable to shareholders for 2023 was a loss of CNY 221,817,878.58, which is an 81.91% increase in loss compared to a loss of CNY 121,938,109.79 in 2022 [25]. - The company anticipates a 12% growth in net profit for the upcoming fiscal year, driven by increased sales and operational efficiency [19]. - The company reported a total revenue of approximately ¥507 million in 2023, representing a year-on-year increase of 53.71% compared to ¥329 million in 2022 [59]. - The company incurred a total loss of approximately ¥240 million, with a net loss attributable to shareholders of approximately ¥221 million, primarily due to asset impairment and increased financial costs [55]. - The company reported a total revenue of 1.5 billion RMB for the fiscal year 2023, representing a year-over-year increase of 15% [127]. Market Expansion and Strategy - The company is focusing on expanding its market presence, particularly in the animal health sector, aiming for a 20% increase in market share by 2025 [19]. - The company is exploring potential mergers and acquisitions to strengthen its product portfolio and market reach [19]. - The company plans to expand its product offerings in new materials technology and electronic materials manufacturing [24]. - The company is actively expanding its market presence in both domestic and international markets, focusing on product structure adjustment and technological development [43]. - The company is focusing on the development of green and efficient veterinary drug products to enhance its product structure and market resilience [56]. - The company is considering strategic acquisitions to enhance its market position, with a budget of 300 million RMB allocated for potential deals [127]. Research and Development - New product development initiatives are underway, with an investment of approximately 10 million yuan allocated for R&D in 2024 [19]. - The company has accumulated 22 invention patents and 15 utility model patents as of the announcement date, reflecting strong R&D capabilities [45]. - The company’s R&D personnel increased to 164 in 2023, a 90.70% increase from 86 in 2022, with R&D personnel accounting for 16.53% of the total workforce [71]. - R&D investment amounted to ¥27,530,726.83 in 2023, representing a 26.14% increase from ¥21,824,916.67 in 2022, while the R&D investment as a percentage of operating revenue decreased to 5.43% from 6.62% [71]. Sustainability and Environmental Initiatives - The company aims to enhance its sustainability practices, with a target of reducing carbon emissions by 15% over the next three years [19]. - The company is committed to complying with national environmental laws and regulations, ensuring sustainable operations [161]. - The company has implemented various environmental protection measures and received multiple approvals for its projects [162]. - The company invested a total of 18.74 million yuan in environmental protection, including greening, pollution control, and environmental taxes during the reporting period [170]. - The company has established online monitoring systems for wastewater and emissions, ensuring compliance with environmental standards since the trial production began on May 9, 2022 [168]. Operational Challenges - The company has identified risks related to supply chain disruptions and regulatory changes, which may impact future performance [4]. - The domestic livestock breeding market is currently sluggish, leading to a decline in demand for veterinary drugs and a continuous drop in the prices of major veterinary raw materials, creating operational pressure for companies [37]. - The company has faced operational pressure in its animal health products due to a sluggish downstream breeding market and declining prices in the veterinary drug industry [56]. Corporate Governance - The company is committed to maintaining transparency and accuracy in its financial reporting, as emphasized by its management team [4]. - The company has ensured compliance with corporate governance standards and improved its internal control systems during the reporting period [110]. - The company has a complete human resources management system, ensuring independence in personnel management and decision-making without interference from the controlling shareholder [114]. - The company has not engaged in any related party transactions that would compromise its operational independence [113]. Financial Management - The cash flow from operating activities showed a significant decline, with a net outflow of CNY 186,758,862.03 in 2023, compared to an outflow of CNY 8,833,005.89 in 2022, marking a 2,014.14% increase in cash outflow [25]. - The company has reported uncertainty regarding its ability to continue as a going concern due to negative net profits over the past three years [26]. - The company has not engaged in any securities or derivative investments during the reporting period [88][89]. - The company has not identified any significant internal control deficiencies during the reporting period [154]. Employee Management - The total number of employees at the end of the reporting period is 992, with 607 in the parent company and 385 in major subsidiaries [143]. - The company has implemented a skill-level salary system, which is regularly assessed and linked to monthly performance bonuses [144]. - The employee stock ownership plan involved 75 participants, with a total subscription amount of approximately 35.704 million yuan, and the actual subscribed shares were 35.704 million [150]. Future Outlook - The company has provided guidance for 2024, expecting revenue growth of 10% to 12% [127]. - New product launches are anticipated to contribute an additional 200 million RMB in revenue in 2024 [127]. - The company plans to increase its marketing budget by 25% to support new product launches and market expansion efforts [127].

Financial Performance - The company's revenue for Q1 2024 was CNY 160,395,845.10, representing a 60.09% increase compared to CNY 100,190,694.85 in the same period last year[5]. - The net loss attributable to shareholders was CNY -31,342,797.54, a significant decline of 208.94% from CNY -10,145,375.67 in the previous year[5]. - The total operating revenue for Q1 2024 was CNY 160,395,845.10, an increase of 60.2% compared to CNY 100,190,694.85 in the same period last year[17]. - The net loss for Q1 2024 was CNY 31,573,220.52, compared to a net loss of CNY 10,416,863.97 in Q1 2023, representing an increase in loss of 202.5%[19]. - The company's gross profit margin decreased significantly, with gross profit for Q1 2024 at CNY -28,071,091.12, compared to CNY -10,976,905.22 in Q1 2023[19]. Cash Flow and Liquidity - The net cash flow from operating activities improved by 75.38%, reaching CNY -15,243,576.62, compared to CNY -61,917,676.50 in the prior year[5]. - Total cash inflow from operating activities was 146,288,322.70 CNY, compared to 150,240,392.34 CNY in the previous year, reflecting a decrease of approximately 2.3%[21]. - Cash outflow from operating activities decreased to 161,531,899.32 CNY from 212,158,068.84 CNY, marking a reduction of about 23.9%[21]. - The ending balance of cash and cash equivalents was 68,380,217.19 CNY, compared to 42,933,481.60 CNY at the end of Q1 2023, indicating an increase of about 59.5%[22]. - The company received 6,249,871.39 CNY in tax refunds, down from 10,920,206.35 CNY in the previous year[21]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,953,475,326.13, a slight decrease of 0.59% from CNY 1,965,009,357.76 at the end of the previous year[5]. - The total liabilities increased to CNY 1,569,477,589.56 in Q1 2024, compared to CNY 1,550,898,558.00 in Q1 2023, reflecting a growth of 1.6%[16]. - The company's equity attributable to shareholders decreased to CNY 381,297,608.33 in Q1 2024 from CNY 411,287,522.61 in Q1 2023, a decline of 7.3%[16]. Operational Metrics - The company reported a significant increase in accounts receivable, which rose by 38.10% to CNY 118,849,696.89 due to increased sales of gel films[7]. - The company's management expenses increased by 73.89% to CNY 12,219,131.83, attributed to the integration of gel film subsidiary expenses[7]. - The financial expenses surged by 141.84% to CNY 16,270,060.42, primarily due to increased financing and interest expenses on project loans[7]. - Accounts receivable increased from 86,059,203.01 RMB to 118,849,696.89 RMB, representing a growth of about 38.2%[14]. - Inventory rose from 201,894,404.60 RMB to 210,229,326.59 RMB, an increase of approximately 4.6%[14]. - Fixed assets increased from 703,254,518.77 RMB to 909,638,726.12 RMB, reflecting a growth of about 29.3%[14]. Future Plans and Developments - The company plans to continue expanding its product offerings and market presence, focusing on the development of new technologies and products[5]. - The company plans to sell certain fixed assets and land use rights for 67.5 million RMB to a related party, Fujian Putan Thermal Energy Co., Ltd.[12]. - The company has not disclosed any new product or technology developments in the current report[11]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 11,643[10]. - The largest shareholder, Shanghai Kangyi Investment Co., Ltd., holds 30.43% of shares, totaling 47,291,400 shares[10]. - There are no changes in the top 10 shareholders due to margin trading activities[11]. - The company has not identified any related party relationships among the other shareholders[11].

证券代码：002868 证券简称：绿康生化 公告编号：2024-033 绿康生化股份有限公司 | | | | | | 本 | 次 | | | 已质押股份 | | 未质押股份 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 本 | 次 | | | | | 情况 | | 情况 | | | | | | | | 质 | 押 | | | | | | | | 股 | | | 质 | 押 | | | 占其 | 占公 | | 占 | | 占 | | | | | | | 后 | 质 | | | 已质押 | | 未质押 | | | 东 | 持股数量 | 持股比 | 前 | 质 | | | 所持 | 司总 | | 已 | | 未 | | | | | | | 押 | 股 | | | 股份限 | | 股份限 | | | 名 | （股） | 例 | 押 | 股 | | | 股份 | 股本 | | 质 | | 质 | | | | | | | 份 | 数 | | | 售和冻 | | 售和冻 | | | 称 ...

本法律意见书中不存在虚假、严重误导性陈述及重大遗漏，否则本所律师愿 意承担相应的法律责任。 上海澄明则正律师事务所 法律意见书 上海澄明则正律师事务所 关于绿康生化股份有限公司 2024 年第二次临时股东大会的法律意见书 致：绿康生化股份有限公司 上海澄明则正律师事务所（以下简称"本所"），接受绿康生化股份有限公 司（以下简称"公司"）的委托，指派本所律师出席公司 2024 年第二次临时股 东大会（以下简称"本次股东大会"），并对公司本次股东大会进行见证，并根 据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国 证券法》（以下简称"《证券法》"）、《上市公司股东大会规则》（以下简称 "《股东大会规则》"）以及《绿康生化股份有限公司章程》（以下简称"《公 司章程》"）等规定出具《上海澄明则正律师事务所关于绿康生化股份有限公司 2024 年第二次临时股东大会的法律意见书》（以下简称"本法律意见书"）。 本所律师按照中华人民共和国（以下简称"中国"，仅为本法律意见书之目 的，不包括香港特别行政区、澳门特别行政区和台湾地区）现行法律、法规的规 定对本次股东大会的召集、召开程序是否合法及是否符合《公 ...

证券代码：002868 证券简称：绿康生化 公告编号：2024-032 绿康生化股份有限公司 关于 2024 年第二次临时股东大会决议的公告 二、提案审议表决情况 本次会议以现场投票与网络投票相结合的方式对议案进行表决，具体表决结 果如下： （一）《关于公司出售资产暨关联交易的议案》 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会召开期间不存在否决或变更提案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 3、本次股东大会采取现场投票表决和网络投票表决相结合的方式进行。 一、会议召开和出席情况 绿康生化股份有限公司（以下简称"公司"或"绿康生化"）2024 年第二次 临时股东大会于 2024 年 3 月 29 日在福建省浦城县园区大道 6 号公司综合办公 楼二楼第一会议室召开，会议采取现场结合网络投票方式举行。参加本次会议的 股东及股东代表共计 13 人，代表有表决权的股份 80,621,305 股，占公司总股本 的 51.8746%。其中，出席现场会议的股东及股东代表 7 人，代表有表决权的股 份 38,058,0 ...

证券代码：002868 证券简称：绿康生化 公告编号：2024-031 绿康生化股份有限公司 关于为全资子公司开展融资租赁暨 担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、截至本公告日，公司为合并报表范围内的子公司提供担保额度总金额为 90,851.67 万元，超过最近一期经审计净资产 100%。公司为合并报表范围内资产 负债率超过 70%的子公司提供担保金额为 86,261.67 万元，超过公司最近一期经 审计净资产 50%。敬请投资者注意投资风险，理性投资。 2、截至本公告日，公司正在履行的对外担保均系为合并报表范围内的子公 司提供担保，担保风险可控。 3、截至本公告日，公司不存在对合并报表范围外的单位、个人或关联方提 供担保，亦不存在逾期担保。 一、融资租赁及担保情况概述 （一）融资租赁概述 绿康生化股份有限公司（以下简称"绿康生化"或"公司"）全资子公司绿 康（玉山）胶膜材料有限公司（以下简称"绿康玉山"）为拓宽融资渠道，优化 融资结构，满足生产经营中的资金需求，与金源华兴融资租赁有限公司（以下简 称"金源租赁"）签署 ...